Hear how the experts test for HER2, HER3, and TROP2 in metastatic breast cancer, then learn how to optimally leverage established and emerging therapies targeting these biomarkers.
Download this short summary slideset of key takeaway points from a live presentation on HER2 testing and how this can inform treatment in metastatic breast cancer.
Download this short summary slideset of key takeaway points from a live presentation on approved and emerging investigational HER2-, HER3-, and TROP2-targeted therapies for metastatic breast cancer.
Download this slideset for expert perspectives on key nuances of HER2 testing in metastatic breast cancer and how test results inform HER2-targeted therapy decisions.
Download this slideset to review key data and expert perspectives on approved and emerging investigational HER2-, HER3-, and TROP2-targeted therapies for metastatic breast cancer.
Download this PDF summarizing key points in HER2, HER3, and TROP2 testing and targeted therapy for patients with breast, GI, and lung cancers.
What is new in testing for HER2 in breast cancer and beyond? How might newly approved and emerging therapies targeting HER2, HER3, and TROP2 affect your practice? Here’s my take.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.